MedTrace Logo

Safety and Efficacy Active Drug vs. Placebo in Subjects With Asthma

NCT04987944 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-07-19

Study results available
· View outcomes & findings →

Summary

This study is a double-blind, parallel-group, randomized study of active drug vs placebo in asthma.

Conditions

Interventions

DRUG

Zavegepant

150 mg BID

DRUG

Placebo

Placebo matching active drug

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-18
Primary Completion
2023-03-29
Completion
2023-04-04

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04987944 on ClinicalTrials.gov